Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 2, 1998, Pages 182-188

  Moorman, Anne C ^a,c   Von Bargen, Jennifer C ^a   Palella, Frank J ^b   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; Breakthrough; HIV; Opportunistic infection; Pneumocystis carinii pneumonia; Prophylaxis

Indexed keywords

ATOVAQUONE; COTRIMOXAZOLE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE;

EID: 0031654635     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199810010-00013     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention, HIV/AIDS Surveillance Rep 1997;8:18.
2. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995;123:993-6.
3. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
4. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;1:439-47.
5. Catt S, Stygall J, Catalan J. Acceptance of zidovudine (AZT) in early HIV disease: the role of health beliefs. AIDS Care 1995;1:229-35.
6. Kissinger P, Cohen D, Brandon W, Rice J, Morse A, Clark R. Compliance with public sector HIV medical care. J Natl Med Assoc 1995;87:19-24.
7. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev 1996;8:58-71.
8. VonBargen JC, Moorman AC, Holmberg SD, the HOPS Investigators. How many pills do patients with HIV infection take? [letter]. JAMA 1998;280:29.
9. Simon PM, Morse EV, Besch CL. Barriers to compliance among women co-enrolled in a PCP prophylaxis and compliance protocol [abstract TP-472]. In Program and abstracts of the HIV Infection in Women Conference: setting a new agenda (Washington, D.C.). Richmond, VA: Philadelphia Sciences Group, 1995:P109.
10. Ioannidis JP, Cappeleri JC, Skolnik PR, Lau J, Sacks HS. Metaanalysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:177-88.
11. Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA 1995;273:1197-1202.
12. Beard CB, Navin TR. Molecular epidemiology of Pneumocystis carinii pneumonia. Emerg infect Dis 1996;2:147-50.
13. Locke A, Meshnick S, Lane B, et al. Mutations in Pneumocystis carinii associated with prophylaxis breakthroughs in AIDS patients [abstract 3]. In: Program and abstracts of the IV conference on retroviruses and opportunistic infections (Washington, D.C.). Alexandria, VA: Infectious Diseases Society of America, 1997:65.
14. Epstein LJ, Meyer RD, Antonson S, Single SM, Mohsenifar Z. Persistence of Pneumocystis carinii in patients with AIDS receiving chemoprophylaxis. Am J Respir Crit Care Med 1994;150:1456-59.
15. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
16. USPHS/IDS. Prevention of Opportunistic Infection Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46:4-5.
17. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1842-48.
18. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM, et al. A controlled trial of aerosolized pentamidine or trimethoprimsulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
19. Kaplan JE, Hanson D, Jones J, Risk factors for primary PCP in HIV-infected adolescents and adults in the U.S.: should history of AIDS-defining illness be included in the criteria for PCP prophylaxis? [abstract 290]. In Program and abstract of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, D.C.). Alexandria, VA: Infectious Diseases Society of America, 1997:118
20. Palella FJ, Delaney KM, Moorman AC. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.